Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (AVHHL) Cash from Investing Activities (2019 - 2025)

Historic Cash from Investing Activities for AVITA Medical (AVHHL) over the last 7 years, with Q4 2025 value amounting to $11000.0.

  • AVITA Medical's Cash from Investing Activities fell 9955.48% to $11000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $12.5 million, marking a year-over-year decrease of 6667.29%. This contributed to the annual value of $12.5 million for FY2025, which is 6667.29% down from last year.
  • According to the latest figures from Q4 2025, AVITA Medical's Cash from Investing Activities is $11000.0, which was down 9955.48% from -$5.3 million recorded in Q3 2025.
  • AVITA Medical's 5-year Cash from Investing Activities high stood at $42.3 million for Q2 2022, and its period low was -$57.3 million during Q4 2023.
  • In the last 5 years, AVITA Medical's Cash from Investing Activities had a median value of $4.7 million in 2024 and averaged $970777.8.
  • Per our database at Business Quant, AVITA Medical's Cash from Investing Activities tumbled by 1666959.46% in 2021 and then surged by 814885.93% in 2022.
  • AVITA Medical's Cash from Investing Activities (Quarter) stood at -$49.6 million in 2021, then surged by 93.64% to -$3.2 million in 2022, then plummeted by 1714.57% to -$57.3 million in 2023, then surged by 104.31% to $2.5 million in 2024, then crashed by 99.55% to $11000.0 in 2025.
  • Its last three reported values are $11000.0 in Q4 2025, -$5.3 million for Q3 2025, and $7.0 million during Q2 2025.